New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1:00
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1 month ago
MSNWooGlobe
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1:00
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1 month ago
MSNWooGlobe
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1:00
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1 month ago
MSNWooGlobe
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1:00
New FDA-approved oral treatment advances ESR1 mutation breast cancer care
1 month ago
MSNWooGlobe
FDA Approves INLURIYO + VERZENIO for ESR1 Mutated Advanced Breast Cancer #genetherapy #biotech
0:27
FDA Approves INLURIYO + VERZENIO for ESR1 Mutated Advanced Breast Cancer #genetherapy #biotech
1 month ago
YouTubeMetrivra
🔥10k ❤️ | 5k 💬 | 1k 🔄 | 20k ▶️| Inluriyo (Imlunestrant) The FDA's 2025 Breakthrough in Breast Cancer
1:10
🔥10k ❤️ | 5k 💬 | 1k 🔄 | 20k ▶️| Inluriyo (Imlunestrant) The FDA's 2025 Breakthrough in Breast Cancer
85 viewsNov 3, 2025
YouTubeRxIndianPharmacist | Med Info | US Pharmacy Tips
Eli Lilly and Company has announced a new break through drug Inluriyo. Did you know, an estimated 50% of patients with ER , HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor. In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC. https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-a
0:16
Eli Lilly and Company has announced a new break through drug Inluriyo. Did you know, an estimated 50% of patients with ER , HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor. In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC. https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-a
112 views11 months ago
FacebookSisters Network Inc.
0:54
Lilly's Verzenio Label Expansion for ESR1-mutated Breast Cancer | TechStock² posted on the topic | LinkedIn
1 month ago
linkedin.comTechStock²
#inlexzo #koselugo #inluriyo #wayrilz #denosumab | Kristi Rosa
Oct 4, 2025
linkedin.com
2:45
#fda | Guideline Central
1 month ago
linkedin.comGuideline Central
1:08
Pharma industry news round-up: 21 September 2026 #pharma #news #pharmanews
1 views1 month ago
YouTubepharmaphorum media limited
0:53
MedLingo | Episode 1 #medical #medicalpodcast
3 weeks ago
YouTubeMedLingo
See more
Static thumbnail place holder